Prostate Section

$2,574,499ZIAFY2025CANIH

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Paper 39022660 Paper 38958754 Paper 38953042 Paper 38713024 Paper 38670874 Paper 38651785 Paper 38556436 Paper 38468864 Paper 38370835 Paper 38262813 Paper 37858505 Paper 37811666 Paper 37775447 Paper 37729551 Paper 37423774 Paper 35740662 Paper 35647400 Paper 35633863 Paper 35523680 Paper 35469800 Paper 35314627 Paper 35275101 Paper 35196107 Paper 35183438 Paper 35099572 Paper 34916246 Paper 34854746 Paper 34724140 Paper 34633213 Paper 34598869 Paper 34433302 Paper 34236345 Paper 34181465 Paper 34003127 Paper 33867045 Paper 33847515 Paper 33846112 Paper 33785256 Paper 33736975 Paper 33707581 Paper 33705228 Paper 33676851 Paper 33547722 Paper 33388878 Paper 33384275 Paper 33356479 Paper 33102128 Paper 33023952 Paper 32958429 Paper 32478955 Paper 32315265 Paper 32307270 Paper 32300896 Paper 32275845 Paper 32269146 Paper 32211948 Paper 32190560 Paper 32143993 Paper 32130814 Paper 32109495 Paper 32071877 Paper 32054861 Paper 31940221 Paper 31930156 Paper 31807974 Paper 31676732 Paper 31642740 Paper 31613660 Paper 31502940 Paper 31468153 Paper 30382457 Paper 30239414 Paper 30197041 Paper 29943220 Paper 29940248 Paper 29236593 Paper 28961099 Paper 28840173 Paper 28832304 Paper 28727501 Paper 28634789 Paper 28582632 Paper 28483574 Paper 28440325 Paper 28373133 Paper 28220802 Paper 27864107 Paper 27743850 Paper 27657193 Paper 27613356 Paper 27582434 Paper 27567248 Paper 27529049 Paper 27451403 Paper 27400645 Paper 27391860 Paper 27383502 Paper 27343000 Paper 27336392 Paper 27305918

Abstract

My team's research has been practice changing in regard to the management and detection of prostate cancer. This includes research in the use of MRI to identify regions suspicious for clinically aggressive prostate cancer and the development from concept to commercialization and widespread adoption of a novel prostate biopsy device. Adoption by the medical community has been facilitated by highly cited and high impactful reports in leading journals. Novel approaches and systems were able to better characterize disease states using prostate MRI and targeted biopsies, compared to traditional methods. Better detection of aggressive tumors lowered cancer upgrading rates from 30.2% down to 6.7% for gleason grade group two or higher. These research efforts have helped initiate medicine's adoption towards more targeted diagnosis, personalized focal therapies, and evidence-based practice in the detection and management of prostate cancer. Most recently artificial intelligence software has been developed to better detect prostate cancer by prostate MRI.

View original record on NIH RePORTER →